|
|
Upfront Briefing
The FDA dropped draft guidance for multiple myeloma accelerated approval, pointing to MRD negativity and complete response as endpoints that could speed new therapies to market.
Big-cap tone was upbeat: Johnson & Johnson laid out a strong 2026 growth outlook and is targeting $100 billion in sales, led by cancer and immune drugs.
And in “cash is king” news, Erasca priced an upsized public offering of common stock to raise capital for operations.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,875.6 |
+1.2% |
+0.4% |
| Nasdaq 100 |
25,326.6 |
+1.4% |
+0.3% |
| Russell 2000 |
2,698.2 |
+2.0% |
+8.7% |
| XBI (Biotech ETF) |
128.2 |
+2.3% |
+5.1% |
| Nasdaq Biotech |
5,925.6 |
+2.4% |
+3.8% |
| Clinical Trials ETF (BBC) |
42.4 |
+1.9% |
+9.9% |
|
-
Risk-on session: S&P 500 +1.2% and Nasdaq 100 +1.4% at the close.
-
Biotech outperformed: XBI +2.3% and Nasdaq Biotech +2.4%.
-
Market data: U.S. close Wed 21-Jan-2026.
The Big 3
|
1
|
FDA draft guidance on multiple myeloma accelerated approval
|
-
The FDA has issued draft guidance on using MRD negativity and complete response as endpoints for accelerated approval in multiple myeloma, potentially speeding market access for new therapies.
-
Why it matters:
This is a potential trial-design reset for myeloma: MRD/CR-driven AA could shorten timelines, shift spend toward validated assays + early-depth-of-response strategies, and intensify competition in earlier lines where PFS/OS takes years. Expect faster "signal-to-filing" cycles—and more pressure on differentiation (depth, durability, safety, convenience) across CAR-T, bispecifics, CELMoDs, and novel combos.
-
Source:
Fierce Biotech
-
More:
BioCentury; Endpoints
|
|
2
|
Johnson & Johnson provides strong 2026 growth outlook
|
-
Johnson & Johnson projects strong growth for 2026, aiming for $100 billion in sales, driven by cancer and immune drugs, despite patent challenges.
-
Why it matters:
J&J is a bellwether multiple: a credible 2026 growth guide supports large-cap biopharma sentiment, sets comp anchors for oncology/immunology franchises, and signals how cleanly management expects to work through post-Stelara mix-shift and litigation noise. Strong outlooks also imply continued BD appetite—useful for read-through to late-stage assets in crowded classes.
-
Source:
BioPharma Dive
-
More:
Endpoints; BioSpace
|
|
3
|
Erasca prices upsized public offering of common stock
|
-
Erasca announced the pricing of an upsized public offering of its common stock, aiming to raise capital for its operations.
-
Why it matters:
Another data-point that the follow-on window is open for select SMID caps: extending runway de-risks near-term funding, but dilution can cap upside until catalysts re-rate the story. For investors, watch whether proceeds are tied to a discrete value inflection (trial readouts/registrational path) versus "general corporate purposes."
-
Source:
PR
|
Everything Else that broke
- IntraBio announced plans to seek FDA approval for its rare disease drug after successful Phase 3 trial results. — Endpoints
-
Corvus shares jumped after positive early data for its eczema pill, soquelitinib. —
BioPharma Dive
- The current status of drug pricing negotiations in the European Union is a subject of ongoing debate among stakeholders. — Endpoints
- PulseSight Therapeutics has completed dosing in its Phase 1 clinical trial for PST-611, a treatment for dry AMD/Geographic Atrophy. — PR
- OSE Immunotherapeutics received FDA Orphan Drug Designation for pegrizeprument (VEL-101). — PR
- AB Science secured Japanese patent protection for masitinib's use in progressive multiple sclerosis until 2041. — PR
- A court-appointed official in New Jersey recommended allowing expert testimony in the Johnson & Johnson talc litigation. — Fierce Pharma
- A commentary series explores the biotech market's bull thesis, launch cycle, and the flywheel effect of M&A and IPOs for 2026. — BioCentury
Deal Flow
M&A / BD&L
-
IO Biotech is exploring a potential sale. — BioPharma Dive
-
Qiagen is reportedly weighing strategic options, including a potential sale, amid renewed takeover interest. — Reuters
-
An arbitration tribunal upheld Ipsen's termination of its R&D agreement with Galderma. — PR
VC / Private Financings
-
ErVimmune raised €17M in a Series A first closing to enter the clinic with its lead off-the-shelf cancer vaccine candidate (ErVac01). —
Company PR
-
OpenEvidence raised $250M at a $12B valuation to scale its physician-focused medical AI search platform. —
Reuters
-
Luminate Medical raised €18M in a Series A to scale supportive-care tech for cancer patients. —
Pulse+IT
IPOs / Follow-Ons
-
Erasca priced an upsized public offering of common stock. —
PR
-
BioAge Labs priced an upsized public offering (gross proceeds ~$115M). —
PR
-
Corvus Pharmaceuticals priced an upsized public offering (gross proceeds ~$175M) following its eczema-data pop. —
PR
-
Axogen priced an upsized ~$124M public offering of common stock. —
PR
Academic Corner
- Promoting Fairness in Screening Programs for Late-Career Practitioners. — NEJM
- 2025 FDA approvals: volume maintained, but value remains below average. — Nature RDD
|
|
Filed for today, pending tomorrow. BioBucks Team
|
|
|
